Actively Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Led by Antengene Biologics Limited · Updated on 2026-04-15
156
Participants Needed
22
Research Sites
248 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
CONDITIONS
Official Title
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent before any study procedures
- Age 18 years or older
- Confirmed solid tumor that has progressed despite or is intolerant to standard therapy, or standard therapy not applicable
- Dose Escalation Phase: any solid tumor
- Dose Expansion Phase: Claudin 18.2-positive solid tumors
- Willing to have a biopsy at screening if no tumor tissue sample from the past 36 months is available
- At least one measurable tumor lesion according to RECIST v1.1
- Estimated life expectancy of at least 12 weeks
- ECOG performance status of 0 or 1
- Females of childbearing potential must use adequate contraception until 180 days after treatment ends, not be breastfeeding, and have a negative pregnancy test before dosing
- Males must agree to use effective contraception during the study and for 180 days after the last dose
You will not qualify if you...
- Primary central nervous system disease or CNS metastases
- Prior treatment with a Claudin 18.2 targeting agent
- Chemotherapy, immunotherapy, or investigational cancer treatments within 28 days before the first study dose or still present in the body
- Vaccination within 28 days before the first dose
- Any solid organ transplant; autologous stem cell transplant or CAR-T cell therapy within 6 months before the first dose
- Active infections including hepatitis B or C
- Known HIV infection
- Any unresolved side effects from prior treatments greater than Grade 1 except alopecia
- Pregnant or nursing females
- History of allergic reactions to drugs similar to ATG-022
- Other primary cancers developed within 5 years except those cured locally
- Conditions that may affect study compliance or suitability as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
Cancer Research SA Pty Ltd
Adelaide, Australia
Completed
2
Cabrini Health Limited
Malvern, Australia
Actively Recruiting
3
Integrated Clinical Oncology Network Pty Ltd (Icon)
South Brisbane, Australia
Actively Recruiting
4
Beijing GoBroad Hospital
Beijing, China
Actively Recruiting
5
West China Hospital, Sichuan University
Chengdu, China
Actively Recruiting
6
Fujian Cancer Hospital
Fuzhou, China
Actively Recruiting
7
Anhui Provincial Hospital
Hefei, China
Actively Recruiting
8
The First Affiliated Hospital of Anhui Medical University
Hefei, China
Actively Recruiting
9
Jinan Central Hospital
Jinan, China
Actively Recruiting
10
Gansu provincial cancer hospital [recruiting]
Lanzhou, China
Actively Recruiting
11
The Affiliated Hospital of Qingdao University
Qingdao, China
Actively Recruiting
12
Fudan University Shanghai Cancer Center
Shanghai, China
Actively Recruiting
13
Tongren Hospital Shanghai
Shanghai, China
Actively Recruiting
14
Liaoning Cancer Hospital
Shenyang, China
Actively Recruiting
15
The Fourth Hospital of Hebei Medical University
Shijiangzhuang, China
Actively Recruiting
16
Shanxi provincial cancer hospital
Taiyuan, China
Actively Recruiting
17
Tianjin Medical Universuty Cancer Institute & Hospital
Tianjin, China
Actively Recruiting
18
Hubei Cancer Hospital
Wuhan, China
Actively Recruiting
19
The First affiliated hospital of Xi'An Jiao Tong Ubiversity
Xi'an, China
Actively Recruiting
20
Xuzhou Central Hospital
Xuzhou, China
Actively Recruiting
21
General Hospital of Ningxia Medical University
Yinchuan, China
Actively Recruiting
22
The First Affiliated Hospital of Zhenghzou University
Zhengzhou, China
Actively Recruiting
Research Team
F
Felix Li
CONTACT
S
Sunny He
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here